Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00908388 · ClinicalTrials.gov registry record · NA

Evaluation of the GORE Conformable TAG® Thoracic Endoprosthesis for Treatment of Acute Complicated Type B Aortic Dissection

A NA study, sponsored by W.L.Gore & Associates.

Completed
Registry status
NA
Development phase
50
Enrollment target

NCT00908388 is a NA study that has completed, run by W.L.Gore & Associates. The registered enrollment target is 50 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00908388, a NA study, has completed, sponsored by W.L.Gore & Associates.

COMPLETED
Registry status
NA
Development phase
50 participants
Enrollment target

Study Summary

The primary objective of this study is to determine the safety and efficacy of the GORE Conformable TAG Thoracic Endoprosthesis (CTAG) for treatment of subjects with acute complicated type B aortic dissection.

Interventions

  • DEVICE GORE TAG® Thoracic Endoprosthesis

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2009-10
Est. Completion 2017-02-28
Phase NA

Sponsor

W.L.Gore & Associates

53 total trials

What the Registry Record Tells You About NCT00908388

The ClinicalTrials.gov registry entry for NCT00908388 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is W.L.Gore & Associates, which has 53 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which GORE TAG® Thoracic Endoprosthesis is the first listed.

NCT00908388 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00908388 about?

NCT00908388 is a clinical study titled "Evaluation of the GORE Conformable TAG® Thoracic Endoprosthesis for Treatment of Acute Complicated Type B Aortic Dissection". The primary objective of this study is to determine the safety and efficacy of the GORE Conformable TAG Thoracic Endoprosthesis (CTAG) for treatment of subjects with acute complicated type B aortic dissection.

What is the current status of trial NCT00908388?

This trial is currently completed. It is a NA study. The enrollment target is 50 participants. The study started on 2009-10. Estimated completion is 2017-02-28.

What interventions are being tested in trial NCT00908388?

The interventions under investigation include: GORE TAG® Thoracic Endoprosthesis (DEVICE).

Who is sponsoring clinical trial NCT00908388?

This trial is sponsored by W.L.Gore & Associates, which has 53 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.